Balance Sheet Details

3 Months Ended

Mar. 31, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

5. Balance Sheet Details

Inventory consisted of the following (in thousands):


	March 31, 2024		December 31, 2023
Finished goods	$	7,576	$	5,001
Work in process		5,549		4,134
Raw material		53,518		31,312
	$	66,643	$	40,447
Reported as:
Inventory	$	61,936	$	35,819
Long-term inventory		4,707		4,628
Total	$	66,643	$	40,447

Amount reported as long-term inventory consisted of raw materials as of March 31, 2024 and December 31, 2023. The Company has raw materials beyond a one year production plan that help limit the exposures from potential supply interruption. Those raw materials beyond the one year production plan were classified as long-term inventory.

Accrued liabilities consisted of the following (in thousands):


	March 31, 2024		December 31, 2023
Accrued sales allowances	$	122,436	$	90,718
Accrued contingent payments		79,583		29,583
Accrued compensation and benefits		26,061		42,718
Accrued research and development services		23,878		32,883
Accrued consulting and professional fees		19,684		18,804
Current portion of lease liabilities		10,453		9,405
Current portion of accrued branded prescription drug fees		7,836		718
Accrued royalties		7,591		8,710
Other		13,743		3,172
	$	311,265	$	236,711